Sinergium Biotech is an Argentine biopharmaceutical company specialized in the research, development, production and marketing of vaccines and highly complex biopharmaceutical products. With unique characteristics worldwide, Sinergium Biotech carries forward an innovative production model of strategic alliances with national and international laboratories allowing: the transfer and availability of state-of-the-art technologies, the autonomy in the production and supply of strategic products which had to be imported before now, the creation of new jobs with highly qualified professionals, the replacement of imports and the generation of a significant export potential.

During the influenza A (H1N1) pandemic, the need of counting in Argentina with a local production plant of vaccines became evident. In 2010 and in alliance with the Swiss company Novartis, the technology transfer process began for the local production of the influenza vaccines in the country. Alliances with North American companies followed this agreement: Pfizer for the production of pneumococcal conjugate vaccine and MSD (Merck, Sharp & Dohme, Argentine subsidiary of Merck & Co) for the production of tetravalent vaccine against the HPV. In turn for the production of monoclonal antibodies, Sinergium Biotech joins Laboratorio Elea, Chemo (with its biotechnology company mAbxience) and PharmADN making a public-private partnership with Instituto Roffo (UBA), Universidad de Quilmes and MinCyT. In 2016, Sinergium Biotech entered into an agreement with Protein Sciences Corporation and Mundo Sano for the joint development of a vaccine against the Zika virus.

 

Alejandro Gil

CEO

Abel Di Gilio

Commercial Director

Fernando Lobos

Business Development Director

Marcelo Argüelles

Administration and Finance Director

Juan Eduardo Ceriani

Operations Director

Analía Acebal

Quality Manager

Sebastián Comellas

Technical Director

Situated in the locality of Garín, Province of Buenos Aires, its production plant has a facility of 20.000 m2. Its annual production capacity reaches 30 million, taking into account: 22 million of pre-filled syringes for vaccines, 4 million of vials and 4 million of pre-filled syringes for biopharmaceuticals.

 

Sinergium Biotech equipment and production process standards are compatible with the highest international rules of Good Manufacturing Practices (GMP – for the initials in English), complying with the guidelines of the North American regulatory agency Food & Drug Administration (FDA) and the European Medicines Agency (EMA). Sinergium Biotech also complies with the national regulations stated by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) (National Administration of Drugs, Food and Medical Technology), which is in line with Mercosur (WHO).

 

The quality of its products is monitored by control and follow-up systems using state-of the-art equipment that guarantee the safety and efficacy of the products.

 

• Syringes filling line (Groninger, Germany)

• Automatic inspection system (EISAI, Japan)

• Semi-automatic syringes filler (Groninger, Germany)

• Semi-automatic vials filler (Groninger, Germany)

• Lyophilizers (IMA, China)

•Cartoning and Packaging (Marchesini, Italy)

• Vials and carpules wahser (Getinge, Sweden)

• Water plant for injection (BRAM-COR, Italy)

Pharmaceutical Equipment of the Plant:

REGIONAL SCOPE

Sinergium Biotech counts with a wide network of offices in all Latin American countries which facilitates and allows integration in the marketing of its products as well as of those it represents for third parties. This network allows an expeditious approach to the private and public markets of these countries that demand vaccines and high quality biotechnological products.

ENVIRONMENTAL CONSCIOUSNESS

Sinergium Biotech is committed to the safety, hygiene and environment.  Procedures of routine and strict regulations of Industrial Safety and Hygiene govern our activity.

 

The implementation of different systems of Environment, Safety and Health allows us a continuous monitoring and improvement.

We work in improving the management of waste through the application of the 3 Rs: Reduce, Re-Use and Recycle.

 

Ruta Panamericana | Km 38.7 | Garín.
Province of Buenos Aires (P1619IEA). Argentina

Call center  (54 11) 3220-7300

 

Copyright 2016 : Sinergium Biotech

ES

EN

ES

EN

ES

EN

Alejandro Gil

CEO

Abdel Di Gilio

Commercial Director

Fernando Lobos

Business Development Director

Marcelo Argüelles

Administration and Finance Director

Juan Eduardo Ceriani

Operations Director

Sebastián Comellas

Quality Manager

Analía Acebal

Technical Director

Situated in the locality of Garín, Province of Buenos Aires, its production plant has a facility of 20.000 m2. Its annual production capacity reaches 30 million, taking into account: 22 million of pre-filled syringes for vaccines, 4 million of vials and 4 million of pre-filled syringes for biopharmaceuticals.

 

Sinergium Biotech equipment and production process standards are compatible with the highest international rules of Good Manufacturing Practices (GMP – for the initials in English), complying with the guidelines of the North American regulatory agency Food & Drug Administration (FDA) and the European Medicines Agency (EMA). Sinergium Biotech also complies with the national regulations stated by the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica (ANMAT) (National Administration of Drugs, Food and Medical Technology), which is in line with Mercosur (WHO).

 

The quality of its products is monitored by control and follow-up systems using state-of the-art equipment that guarantee the safety and efficacy of the products.

 

Pharmaceutical Equipment of the Plant:

• Syringes filling line (Groninger, Germany)

• Automatic inspection system (EISAI, Japan)

• Semi-automatic syringes filler (Groninger, Germany)

• Semi-automatic vials filler (Groninger, Germany)

• Lyophilizers (IMA, China)

•Cartoning and Packaging (Marchesini, Italy)

• Vials and carpules wahser (Getinge, Sweden)

• Water plant for injection (BRAM-COR, Italy)